Cancer Research  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 89-93, January 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagle, D. S.
Right arrow Articles by Blumberg, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagle, D. S.
Right arrow Articles by Blumberg, P. M.

Variation with Embryonic Development and Regional Localization of Specific [3H]Phorbol 12,13-Dibutyrate Binding to Brain1

Denise S. Nagle, Susan Jaken2, Monique Castagna3 and Peter M. Blumberg4

Department of Pharmacology, Harvard Medical School, Boston, Massachusetts 02115

We have previously characterized specific binding of the phorbol ester tumor promoter [20-3H]phorbol 12,13-dibutyrate to several tissues, including mouse skin and brain. We report here that specific binding activity in chicken brain increases dramatically during development. In whole embryonic chicken brain, binding increased from 2.0 to 6.8 to 10.6 pmol/mg of protein at 7, 14, and 20 days, respectively. Adult chicken brain bound 15 pmol/mg of protein. In contrast to specific binding activity, binding affinity remained constant. Substantial regional localization of binding activity within the brain was found. For calf brain, representative values ranged from 4.6 pmol/mg for medulla to 38.1 pmol/mg for frontal lobe. Binding affinity did not vary. Inhibition of binding by postulated neurotransmitters and antagonists was examined. D-Propranolol and quinidine, membrane-stabilizing drugs, inhibited binding competitively, although at mM concentrations.

1 Supported by Grant CA22895 from the NIH.

2 Fellow of the Interdisciplinary Programs in Health, Harvard School of Public Health.

3 Exchange scientist under the United States-France Cancer Program, sponsored by the National Cancer Institute and INSERM. Present address: Centre National de la Recherche Scientifique, 7, Rue Guy-Mocquet, 94800 Villejuif, France.

4 Recipient of a Research Career Development Award from the NIH. To whom requests for reprints should be addressed.

Received 4/14/80. Accepted 9/26/80.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.